Every year millions of people die from infectious diseases caused by viruses and virally induced cancer. Up to today the specific treatment of viral infection remains a challenge due to limited availability of effective antiviral agents. Our research focus lies in the discovery of ‘protein degrader’ molecules to specifically target viral proteins in the human cell.

Latest since the Sars-CoV-2 pandemic it is obvious that effective broad-band antiviral substances are urgently required. Our development platforms allow for the discovery of novel antivirals to contribute to the global effort to treat viral infections.